ELF-3 and TSC-1 as potential markers of recurrence in low-risk non–muscle-invasive bladder cancer
Open Access
- 20 June 2026
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Abstract
Tumor recurrence is a major clinical challenge in low-risk non-muscle invasive bladder cancer (NMIBC). Molecular studies have identified two main subtypesKeywords
All Related Versions
Funding Information
- Tekirdağ Namık Kemal University Scientific Research Projects Committee (NKUBAP.02.TU.22.361)
This publication has 27 references indexed in Scilit:
- Towards Defining Follow-up Strategies for Patients with Primary Intermediate-risk Non–muscle-invasive Bladder CancerEuropean Urology Oncology, 2025
- European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines UpdateEuropean Urology, 2024
- Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patientsUrologic Oncology: Seminars and Original Investigations, 2022
- WNT7B represses epithelial-mesenchymal transition and stem-like properties in bladder urothelial carcinomaBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2022
- Comprehensive Molecular Characterization of Muscle-Invasive Bladder CancerCell, 2017
- Bladder Cancer Incidence and Mortality: A Global Overview and Recent TrendsEuropean Urology, 2017
- Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical UseEBioMedicine, 2016
- T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-II α , survivin, and E-cadherinHuman Pathology, 2016
- The role of GATA3 in breast carcinomas: a reviewHuman Pathology, 2016
- Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) TumorsThe American Journal of Pathology, 2001